

PharmaBridge Agentic Report

Query: Patent landscape for donanemab and expiry timelines

Publications

- Donanemab in Early Alzheimer's Disease — New England Journal of Medicine (2021)
- Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials — Journal of Alzheimer's

Patents

- US9902769B2 — Humanized Antibodies that Recognize Amyloid-Beta Peptide (exp: 2033-03-15)
- US10597462B2 — Methods of Treating Alzheimer's Disease with Anti-Amyloid Antibodies (exp: 2037-05-